EichorEICHOR
Location: Waukee Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Waukee

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · University of Iowa Health Care. ( Site 0057) · Merck Sharp & Dohme LLC · NCT06136559MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT05564390Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · NRG Oncology · NCT05624996Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · Alliance for Clinical Trials in Oncology · NCT07321652Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · UI Health Care Mission Cancer and Blood - Waukee Clinic · Alliance for Clinical Trials in Oncology · NCT07091617Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · UI Health Care Mission Cancer and Blood - Waukee Clinic · SWOG Cancer Research Network · NCT06769126Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · UI Health Care Mission Cancer and Blood - Waukee Clinic · NRG Oncology · NCT06532279Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · NRG Oncology · NCT05174169ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · Alliance for Clinical Trials in Oncology · NCT06876714A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-
Phase 2 · Mission Blood & Cancer Care ( Site 0114) · Merck Sharp & Dohme LLC · NCT06890884Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT04269902Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · Canadian Cancer Trials Group · NCT06592924Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2 · Research Site · AstraZeneca · NCT06526793E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · NRG Oncology · NCT06748222A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treat
Phase 3 · Research Site · AstraZeneca · NCT06764875Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent
Phase 2 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT06900595Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · University of Iowa Health Care, Mission Cancer + Blood · Revolution Medicines, Inc. · NCT06881784A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · Mission Cancer Blood · Janssen Research & Development, LLC · NCT07258511Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT07061964Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · UI Health Care Mission Cancer and Blood - Waukee Clinic · NRG Oncology · NCT05327686Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · ECOG-ACRIN Cancer Research Group · NCT04566328De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · NRG Oncology · NCT04852887mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · Alliance for Clinical Trials in Oncology · NCT05677490Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT07198074A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar
Phase 3 · University of Iowa Health Care · Janssen Research & Development, LLC · NCT05552222Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · National Cancer Institute (NCI) · NCT06058377A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · Mission Cancer and Blood · BeOne Medicines · NCT06943872Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · UI Health Care Mission Cancer and Blood - Waukee Clinic · Alliance for Clinical Trials in Oncology · NCT07215910An Internet-based Program to Help Cancer Survivors Manage Pain
NA · UI Health Care Mission Cancer and Blood - Waukee Clinic · Wake Forest University Health Sciences · NCT04462302
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.